Logo image of CBAY

CYMABAY THERAPEUTICS INC (CBAY) Stock Fundamental Analysis

NASDAQ:CBAY - Nasdaq - US23257D1037 - Common Stock - Currency: USD

32.48  +0.01 (+0.03%)

After market: 32.48 0 (0%)

Fundamental Rating

3

Taking everything into account, CBAY scores 3 out of 10 in our fundamental rating. CBAY was compared to 193 industry peers in the Pharmaceuticals industry. The financial health of CBAY is average, but there are quite some concerns on its profitability. CBAY is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year CBAY has reported negative net income.
CBAY had a negative operating cash flow in the past year.
In the past 5 years CBAY always reported negative net income.
In the past 5 years CBAY always reported negative operating cash flow.
CBAY Yearly Net Income VS EBIT VS OCF VS FCFCBAY Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

The Return On Assets of CBAY (-24.24%) is comparable to the rest of the industry.
With a decent Return On Equity value of -36.05%, CBAY is doing good in the industry, outperforming 64.18% of the companies in the same industry.
Industry RankSector Rank
ROA -24.24%
ROE -36.05%
ROIC N/A
ROA(3y)-47.81%
ROA(5y)-45.31%
ROE(3y)-132.2%
ROE(5y)-97.5%
ROIC(3y)N/A
ROIC(5y)N/A
CBAY Yearly ROA, ROE, ROICCBAY Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CBAY so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CBAY Yearly Profit, Operating, Gross MarginsCBAY Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -100 -200 -300

More info and screens

6

2. Health

2.1 Basic Checks

CBAY does not have a ROIC to compare to the WACC, probably because it is not profitable.
CBAY has more shares outstanding than it did 1 year ago.
CBAY has more shares outstanding than it did 5 years ago.
The debt/assets ratio for CBAY has been reduced compared to a year ago.
CBAY Yearly Shares OutstandingCBAY Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M
CBAY Yearly Total Debt VS Total AssetsCBAY Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

2.2 Solvency

An Altman-Z score of 12.87 indicates that CBAY is not in any danger for bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 12.87, CBAY belongs to the top of the industry, outperforming 89.05% of the companies in the same industry.
A Debt/Equity ratio of 0.34 indicates that CBAY is not too dependend on debt financing.
CBAY has a worse Debt to Equity ratio (0.34) than 60.20% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Altman-Z 12.87
ROIC/WACCN/A
WACC8.71%
CBAY Yearly LT Debt VS Equity VS FCFCBAY Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100M 200M

2.3 Liquidity

CBAY has a Current Ratio of 10.96. This indicates that CBAY is financially healthy and has no problem in meeting its short term obligations.
CBAY has a better Current ratio (10.96) than 87.56% of its industry peers.
A Quick Ratio of 10.96 indicates that CBAY has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 10.96, CBAY belongs to the best of the industry, outperforming 87.56% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.96
Quick Ratio 10.96
CBAY Yearly Current Assets VS Current LiabilitesCBAY Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 100M 200M 300M 400M

More info and screens

4

3. Growth

3.1 Past

CBAY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 19.83%, which is quite good.
EPS 1Y (TTM)19.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 34.83% on average over the next years. This is a very strong growth
CBAY is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 87.60% yearly.
EPS Next Y-50.27%
EPS Next 2Y-4.63%
EPS Next 3Y18.9%
EPS Next 5Y34.83%
Revenue Next Year-62.23%
Revenue Next 2Y92.15%
Revenue Next 3Y99.83%
Revenue Next 5Y87.6%

3.3 Evolution

CBAY Yearly Revenue VS EstimatesCBAY Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
CBAY Yearly EPS VS EstimatesCBAY Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 2 -2 4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for CBAY. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CBAY. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CBAY Price Earnings VS Forward Price EarningsCBAY Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CBAY Per share dataCBAY EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2

4.3 Compensation for Growth

CBAY's earnings are expected to grow with 18.90% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-4.63%
EPS Next 3Y18.9%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CBAY!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CYMABAY THERAPEUTICS INC

NASDAQ:CBAY (3/21/2024, 8:15:47 PM)

After market: 32.48 0 (0%)

32.48

+0.01 (+0.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-28 2024-02-28/amc
Earnings (Next)05-13 2024-05-13/amc
Inst Owners0.08%
Inst Owner Change0%
Ins Owners0.24%
Ins Owner Change0%
Market Cap3.73B
Analysts53.75
Price Target33.15 (2.06%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-9.02%
Min EPS beat(2)-11.02%
Max EPS beat(2)-7.02%
EPS beat(4)1
Avg EPS beat(4)-36.69%
Min EPS beat(4)-223.89%
Max EPS beat(4)95.16%
EPS beat(8)3
Avg EPS beat(8)-17.37%
EPS beat(12)3
Avg EPS beat(12)-17.86%
EPS beat(16)5
Avg EPS beat(16)-9.71%
Revenue beat(2)1
Avg Revenue beat(2)-37.13%
Min Revenue beat(2)-100%
Max Revenue beat(2)25.75%
Revenue beat(4)2
Avg Revenue beat(4)8.25%
Min Revenue beat(4)-100%
Max Revenue beat(4)207.25%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)5.69%
PT rev (3m)31.31%
EPS NQ rev (1m)0.71%
EPS NQ rev (3m)-0.67%
EPS NY rev (1m)-4.69%
EPS NY rev (3m)-5.59%
Revenue NQ rev (1m)-100%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-33.96%
Revenue NY rev (3m)-25.58%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 119.97
P/FCF N/A
P/OCF N/A
P/B 12.76
P/tB 12.76
EV/EBITDA N/A
EPS(TTM)-0.97
EYN/A
EPS(NY)-1.46
Fwd EYN/A
FCF(TTM)-0.64
FCFYN/A
OCF(TTM)-0.63
OCFYN/A
SpS0.27
BVpS2.55
TBVpS2.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -24.24%
ROE -36.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-47.81%
ROA(5y)-45.31%
ROE(3y)-132.2%
ROE(5y)-97.5%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.07
Health
Industry RankSector Rank
Debt/Equity 0.34
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 65.35%
Cap/Sales 1.43%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.96
Quick Ratio 10.96
Altman-Z 12.87
F-Score6
WACC8.71%
ROIC/WACCN/A
Cap/Depr(3y)33.17%
Cap/Depr(5y)31.77%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)19.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y-50.27%
EPS Next 2Y-4.63%
EPS Next 3Y18.9%
EPS Next 5Y34.83%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-62.23%
Revenue Next 2Y92.15%
Revenue Next 3Y99.83%
Revenue Next 5Y87.6%
EBIT growth 1Y-9.21%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-75.82%
EBIT Next 3Y41.95%
EBIT Next 5YN/A
FCF growth 1Y13.36%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y13.74%
OCF growth 3YN/A
OCF growth 5YN/A